Cargando…
ST6Gal1: Oncogenic signaling pathways and targets
The Golgi-sialyltransferase ST6Gal1 (βgalactosidase α2,6 sialyltransferase 1), adds the negatively charged sugar, sialic acid, to the terminal galactose of N-glycosylated proteins. Upregulation of ST6Gal1 is observed in many malignancies, and a large body of research has determined that ST6Gal1-medi...
Autores principales: | GC, Sajina, Bellis, Susan L., Hjelmeland, Anita B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465715/ https://www.ncbi.nlm.nih.gov/pubmed/36106023 http://dx.doi.org/10.3389/fmolb.2022.962908 |
Ejemplares similares
-
α2,6 Sialylation mediated by ST6GAL1 promotes glioblastoma growth
por: GC, Sajina, et al.
Publicado: (2022) -
Deficiency in ST6GAL1, one of the two α2,6-sialyltransferases, has only a minor effect on the pathogenesis of prion disease
por: Makarava, Natallia, et al.
Publicado: (2022) -
Biosynthesis of α-Gal Epitopes (Galα1-3Galβ1-4GlcNAc-R) and Their Unique Potential in Future α-Gal Therapies
por: Galili, Uri
Publicado: (2021) -
Sox2 promotes expression of the ST6Gal-I glycosyltransferase in ovarian cancer cells
por: Dorsett, Kaitlyn A., et al.
Publicado: (2019) -
CUX1 Facilitates the Development of Oncogenic Properties Via Activating Wnt/β-Catenin Signaling Pathway in Glioma
por: Feng, Fan, et al.
Publicado: (2021)